COMMUNIQUÉS West-GlobeNewswire

Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

03/04/2024 - 07:00

Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule [...]

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

03/04/2024 - 07:00

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s [...]

Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization)

03/04/2024 - 05:23

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our” or “us”) hereby announces that we resolved, at a meeting of our Board of Directors held on March 29, 2024, to enter into a [...]

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

03/04/2024 - 01:00

LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]

Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction

03/04/2024 - 00:30

Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra’s breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the [...]

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

02/04/2024 - 23:46

FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median radiographic progression free [...]

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/04/2024 - 23:00

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

CENTOGENE Receives Nasdaq Non-Compliance Notice

02/04/2024 - 22:30

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in [...]

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

02/04/2024 - 22:30

REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117 [...]

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS

02/04/2024 - 22:30

SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE ® [...]

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/04/2024 - 22:29

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

02/04/2024 - 22:15

Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapy Confirmation of [...]

Nanobiotix annonce la finalisation de la partie escalade de la Phase 1 et la détermination de la dose recommandée pour la Phase 2 de NBTXR3 dans le traitement du cancer du poumon récurrent, inopérable et pouvant être réirradiés

02/04/2024 - 22:15

Établissement de la dose recommandée pour la Phase 2 de NBTXR3 pour le traitement des patients atteints d’un cancer du poumon non à petites cellules (CPNPC) récurrent et inopérable qui ont déjà été traités par une [...]

HeartSciences to Present at the LD Micro Invitational XIV Conference

02/04/2024 - 22:15

Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology [...]

OneMedNet Completes Securities Purchase Agreement, Solidifying Cash Position to Accelerate Growth

02/04/2024 - 22:08

Cash Infusion Provides Significant Cash Runway of Up to $4.54 Million MINNEAPOLIS, April 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of [...]

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

02/04/2024 - 22:05

SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial [...]

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/04/2024 - 22:05

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 1, 2024, [...]

Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue

02/04/2024 - 22:05

Announces CFO transition SEATTLE, April 02, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

02/04/2024 - 22:05

Research supports azenosertib’s potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agents NEW YORK [...]